Prodesse Gets FDA OK for C. Difficile Assay | GenomeWeb

NEW YORK (GenomeWeb News) – Prodesse announced after the close of the market Thursday that the US Food and Drug Administration has cleared for marketing the firm's ProGastro Cd Assay.

The real-time PCR assay detects toxigenic strains of Clostridium difficile, a healthcare-associated infection that affects around 500,000 patients in the US annually. The test provides results in as little as three hours, said Prodesse.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.